#United States #San Francisco #Monteverde Associates #Nestlé #Aimmune Therapeutics

Proposed Settlement Announced for Aimmune Therapeutics Shareholders

In a significant development for former shareholders, Monteverde & Associates PC and Kahn Swick & Foti, LLC have announced a proposed class action settlement regarding Aimmune Therapeutics, Inc. This settlement pertains to all record and beneficial holders of common stock during specified periods related to the tender offer by Société des Produits Nestlé S.A. (Nestlé) and SPN Mergersub, Inc.

Background

The lawsuit stems from the events surrounding a merger that occurred on October 13, 2020. During the tender offer phase from September 14 to October 9, 2020, shareholders had the opportunity to exchange their Aimmune shares for a price of $34.50 per share. The court is set to review the proposed settlement amounting to $27.5 million, which aims to address claims related to this merger.

Key Hearing Details

A crucial hearing will be conducted on July 18, 2025, at 9:00 AM, at the U.S. District Court for the Northern District of California in San Francisco. Shareholders are encouraged to check the Settlement Class website for the latest details regarding whether the hearing will be held in-person or virtually.

The main objectives for this hearing are:
1. To determine if the proposed settlement is fair, reasonable, and adequate.
2. To decide whether to enter a Final Judgment that dismisses the litigation with prejudice and releases the related claims.
3. To examine the Plan of Allocation for the Net Settlement Fund and its fairness.
4. To deliberate on the application for attorney's fees and expenses, including potential awards to co-lead plaintiffs.

Important Deadlines

For those who held Aimmune shares during the specified class period and wish to share in the distribution of the Net Settlement Fund, it is crucial to submit a Proof of Claim and Release by mail or online by June 6, 2025. Additionally, any shareholders wishing to exclude themselves from the class action must also do so by this date.

Failure to act before the deadline may result in being legally bound by the court’s judgment regarding the settlement.

For those who have not yet received the necessary Notice of Pendency and Proposed Settlement, copies can be requested through various means, including contacting RG/2 Claims Administration LLC.

Filing Objections

If any class member wishes to raise objections regarding the settlement or associated fees, these must be submitted to the court by June 6, 2025. They can be filed electronically or mailed to the clerk’s office. However, it is advised not to contact the court directly regarding this notice, as inquiries related to the settlement should be directed to Class Counsel.

Class Counsel Details

Class Counsel for this case includes Monteverde & Associates, PC and Kahn Swick & Foti, LLC. Details for contacting these firms are available for those needing further clarification regarding the settlement or their rights as class members.

Conclusion

This proposed settlement marks a pivotal moment for former Aimmune shareholders, providing an opportunity for compensation and the chance for a fair resolution of ongoing claims. Attention to upcoming court dates and submission deadlines is crucial to ensure that shareholders protect their rights and interests involved in this litigation.